Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11195433 | 0.82 | KMT2A (0.80) | KDM4EKMT2APOLBRAB9ASMN1; SMN2 | |
| SCHEMBL14223876 | 0.81 | NPC1 (0.56) | KDM4EKMT2ARAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL455628 | 0.81 | NAMPT (0.56) | KMT2ARAB9ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL28277481 | 0.81 | RAB9A (0.65) | KMT2ARAB9ASMN1; SMN2CYP3A4LMNA | |
| SCHEMBL14223443 | 0.80 | RAB9A (0.48) | KDM4EKMT2ARAB9ASMN1; SMN2TDP1 | |
| SCHEMBL4856199 | 0.80 | CYP11B1 (0.51) | KDM4EKMT2APOLBRAB9ASMN1; SMN2 | |
| SCHEMBL4854662 | 0.79 | KMT2A (0.52) | KDM4EKMT2APOLBRAB9ASMN1; SMN2 | |
| SCHEMBL4854969 | 0.79 | RAB9A (0.70) | KMT2APOLBRAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL9596613 | 0.79 | KMT2A (0.58) | KDM4EKMT2ARAB9ASMN1; SMN2CRHBP | |
| SCHEMBL9874228 | 0.79 | NPC1 (0.61) | KDM4EKMT2APOLBRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20040259891-A1 | Novel pyrimidon derivatives | ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259891-A1 | Novel pyrimidon derivatives | TYMS, TPMT, TYMP | KDM4E 4161/4885KMT2A 4298/4885POLB 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.